2024
An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis
Njei B, Osta E, Njei N, Al-Ajlouni Y, Lim J. An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis. Scientific Reports 2024, 14: 8589. PMID: 38615137, PMCID: PMC11016071, DOI: 10.1038/s41598-024-59183-4.Peer-Reviewed Original ResearchConceptsNational Health and Nutrition Examination SurveyRisk of progression to cirrhosisClinical risk indexHealth and Nutrition Examination SurveyControlled attenuation parameter valuesNovel therapeutic optionsLiver stiffness measurementProgression to cirrhosisAspartate aminotransferase levelsNutrition Examination SurveyResource-limited settingsFIB-4Fibrosis scorePlatelet countAminotransferase levelsTherapeutic optionsWaist circumferenceClinically applicable modelExamination SurveyNonalcoholic steatohepatitisFAST scoreEarly identificationElastography measurementsStiffness measurementPatients
2022
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology 2022, 163: 764-774.e1. PMID: 35842345, PMCID: PMC9398982, DOI: 10.1053/j.gastro.2022.06.023.Peer-Reviewed Original ResearchConceptsLean Nonalcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseType 2 diabetes mellitusClinical Practice Updates CommitteeBiopsy-confirmed nonalcoholic steatohepatitisFatty liver diseaseBody mass indexDiabetes mellitusLean individualsLiver diseaseNonalcoholic steatohepatitisLean personsLiver cirrhosisMass indexHepatic steatosisNoninvasive testsManagement of NAFLDSodium-glucose cotransporter 2 inhibitorsGlucagon-like peptide-1 agonistsLysosomal acid lipase deficiencyPrognosis of NAFLDAGA Governing BoardLiver biochemical testsModest weight lossCotransporter 2 inhibitors